Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | HTR3A | P46098 | 9/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780493 | 1.00 | LMNA (0.61) | LMNACYP2C9HTR3ACHRM2CHRM1 | |
| SCHEMBL23475181 | 1.00 | LMNA (0.61) | LMNACYP2C9HTR3ACHRM2CHRM1 | |
| SCHEMBL15058377 | 1.00 | LMNA (0.61) | LMNACYP2C9HTR3ACHRM2CHRM1 | |
| SCHEMBL14232024 | 0.84 | — | — | |
| SCHEMBL15030963 | 0.84 | — | — | |
| SCHEMBL6745315 | 0.81 | — | — | |
| SCHEMBL21146011 | 0.79 | LMNA (0.43) | LMNACYP2C9 | |
| SCHEMBL23475238 | 0.79 | LMNA (0.43) | LMNACYP2C9 | |
| SCHEMBL21145980 | 0.79 | LMNA (0.43) | LMNACYP2C9 | |
| SCHEMBL21145993 | 0.79 | LMNA (0.43) | LMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-05-29 | — | — | US | disclosed |
| WO-2025030163-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-02-06 | — | — | WO | disclosed |
| EP-3312169-B1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-09-15 | — | — | EP | disclosed |
| US-10407443-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| EP-2875012-B1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-20180327421-A1 | 5-HT3 RECEPTOR ANTAGONISTS | ENVOY THERAPEUTICS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-10125145-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-11-13 | — | — | US | disclosed |
| EP-3312169-A1 | 5-HT3 RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | TAKEDA CALIFORNIA, INC. | 2018-03-15 | — | — | US | disclosed |
| EP-2875011-B1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-10 | — | — | EP | disclosed |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
| US-20150182533-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-02 | — | — | US | disclosed |
| US-9012447-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-21 | — | — | US | disclosed |
| EP-2794608-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | Merck Patent GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-20140024644-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
| EP-2674434-A1 | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators | ARES TRADING S.A. (CH) | 2013-12-18 | — | — | EP | disclosed |
| WO-2013091773-A1 | TETRAAZA-CYCLOPENTA[A]INDENYL AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS | MERCK PATENT GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| US-5256656-A | Antiserotonine agent | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1993-10-26 | — | — | US | disclosed |
| US-5187166-A | Also useful as antipsychotic agents | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1993-02-16 | — | — | US | disclosed |
| EP-0469449-A1 | Azabicyclo derivatives | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1992-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10407443-B2 | 5-HT3 receptor antagonists | HTR3A, HTR3B, HTR5A | LMNA 3775/4885CYP2C9 458/4885HTR3A 1/4885 |
| US-20150182533-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR3E | LMNA 4255/4885CYP2C9 1137/4885HTR3A 1/4885 |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | LMNA 3559/4885CYP2C9 405/4885HTR3A 1/4885 |
| US-20180327421-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | LMNA 3775/4885CYP2C9 458/4885HTR3A 1/4885 |
| US-20140024644-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | LMNA 3775/4885CYP2C9 458/4885HTR3A 1/4885 |
| US-20250171431-A1 | HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE | IGF1R, TRHR, TSHR | LMNA 3056/4885CYP2C9 4365/4885HTR3A 786/4885 |
| US-20180072758-A1 | 5HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR3B, HTR5A | LMNA 3514/4885CYP2C9 375/4885HTR3A 1/4885 |
| US-10125145-B2 | 5-HT3 receptor antagonists | HTR3A, HTR3B, HTR5A | LMNA 3775/4885CYP2C9 458/4885HTR3A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.